An open label, prospective, randomized controlled study to compare the efficacy of Ustekinumab with tumor necrosis factor inhibitor in clearing enthesitis in Psoriatic arthritis patients

Trial Profile

An open label, prospective, randomized controlled study to compare the efficacy of Ustekinumab with tumor necrosis factor inhibitor in clearing enthesitis in Psoriatic arthritis patients

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs Ustekinumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Acronyms ECLIPSA
  • Most Recent Events

    • 07 Jul 2017 New trial record
    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top